Current Grant Support
Hyundai Hope on Wheels, “Targeted radiotherapy with alkyl phosphocholine analogs for refractory childhood leukemia” (2019-2021). Otto, PI
Hyundai Hope on Wheels, “Effects of molecular targeted radionuclide therapy on the immune microenvironment in medulloblastoma” (2019-2021). Otto, Mentor for N. Pytel
AACR-St. Baldrick’s, “Immunogenomics to create new therapeutics for high risk childhood cancers” (2017-2021). Otto, Young Investigator
UW ICTR, “Development of pre-clinical models and clinical applications for T cell receptor alpha beta depleted haploidentical stem cell transplant” (2018-2020). Otto, Mentor for S. Rinella
Cannonball Kids’ Cancer Foundation, “TCR-alpha/beta+ and CD19+ depleted KIR/KIR ligand-mismatched haploidentical hematopoietic stem cell transplant and Zoledronate for pediatric relapsed/refractory hematologic malignancies and high risk solid tumors” (2016-2020). Otto, PI
Cellectar Biosciences, Inc., “A phase 1, open-label, dose escalation study of CLR 131 in children and adolescents with select solid tumors, lymphoma, and malignant brain tumors” (2018-ongoing). Otto, site PI
MACC Fund, “Targeted molecular radiotherapy to improve the outcomes in children with malignant brain tumors” (2017-2019). Otto, PI
MACC Fund, “Strategies for improving recovery of immune function following TCRab-depleted hematopoietic stem cell transplantation” (2017-2019). Otto, PI
UW Office of the Vice Chancellor for Research and Graduate Education and the UW Carbone Cancer Center, “Combining radiotherapeutic with antitumor antibody and IL2 to create a potent in situ cancer vaccine” (2016-2019). Otto, Co-PI
Completed Grant Support
St. Baldrick’s, “Improving anti-cancer immune responses to targeted radionuclide therapy” (2018-2019). Otto, PI
NIH/NCI & University of Wisconsin Carbone Cancer Center (P30 CA014520), “TCR-α/β+ and CD19+ depleted KIR/KIR ligand-mismatched haploidentical hematopoietic stem cell transplant and Zoledronate for pediatric relapsed/refractory hematologic malignancies and high risk solid tumors” (2016-2018). Otto, Pilot Grant PI
Hyundai Hope on Wheels, “A novel phospholipid ether analog to combine targeted molecular radiotherapy and immunotherapy in pediatric solid tumors” (2015-2018). Otto, PI
American Association of Immunologists (K. Kloepping fellowship), “A novel phospholipid ether analog to combine targeted molecular radiotherapy and immunotherapy in pediatric solid tumors,” (2016-2017). Otto, Mentor
Midwest Athletes Against Childhood Cancer, “Effect of Zoledronate on engraftment and t-cell development after TCR alpha-ß/CD19-depleted hematopoietic stem cell transplantation” (2015-2017). Otto, PI
NIH/NCI (R21 CA198392), “A cancer-targeted phospholipid ether analog for molecular radiotherapy of pediatric solid tumors” (2015-2017). Otto, PI
Midwest Athletes Against Childhood Cancer, “Clr1404 – A tumor-selective alkyl phospholipid analog for the treatment of pediatric solid malignancies” (2015-2017). Otto, PI
AACR-St. Baldrick’s-SU2C Foundations “Immunogenomics to create new therapies for high-risk childhood cancers” (2013-2017). Otto, Young Investigator
Midwest Athletes Against Childhood Cancer, “Alpha/beta t-cell depleted haploidentical transplantation with post-transplant zoledronic acid to treat recurrent or refractory pediatric malignancies” (2013-2016). Otto, Co-Investigator
Midwest Athletes Against Childhood Cancer, “Development of multifunctional superparamagnetic anti-GD2 nanoparticles for simultaneous molecular imaging, cancer cell targeting and drug delivery” (2011-2015). Otto, PI
Alex’s Lemonade Stand Foundation for Childhood Cancer, “Development of an innovative treatment strategy for neuroblastoma and other pediatric tumors: a novel phospholipid ether analogue and its multifunctional cancer-targeting nanoconstruct” (2012-2014). Otto, PI